lirentelimab

Phase 3Monoclonal antibody

AAllakos Inc.

lirentelimab is one of 77 small molecule programs targeting Eosinophilic Esophagitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Eosinophilic EsophagitisActive, not recruiting

Eosinophilic GastritisActive, not recruiting

Chronic Spontaneous UrticariaActive, not recruiting

Eosinophilic EsophagitisPhase 2/Phase 3

Active, not recruiting

Eosinophilic GastritisPhase 3

Active, not recruiting

Chronic Spontaneous UrticariaPhase 2

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Eosinophilic Esophagitis

#DrugCompanyPhaseTrials

Flovent

GSK

Approved

2 2

Flovent

PParatek Pharmaceuticals Inc

Approved

5 3

Prilosec

DDexcel Pharma Technologies Ltd.

Cinqair

2 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

10 6

Fasenra

AstraZeneca

Phase 3

1 7

Tezspire

AstraZeneca

Phase 3

1 8

Xolair

Roche

Phase 2

2 9

Velsipity

Pfizer

Phase 2

1 10

Asmanex

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Eosinophilic Gastritis2 trials

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Completed·AAllakos Inc.·Phase 3·NCT04322604·181 enrolled

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Completed·AAllakos Inc.·Phase 3·NCT04620811·159 enrolled

Chronic Spontaneous Urticaria1 trial

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Terminated·AAllakos Inc.·Phase 2·NCT05528861·127 enrolled

Eosinophilic Esophagitis1 trial

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Completed·AAllakos Inc.·Phase 2/3·NCT04322708·277 enrolled

Adult1 trial

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Completed·AAllakos Inc.·Phase 1·NCT04324268·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for lirentelimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — lirentelimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for lirentelimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Allakos Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: AAllakos Inc.

lirentelimab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Eosinophilic Gastritis2 trials

Chronic Spontaneous Urticaria1 trial

Eosinophilic Esophagitis1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News